Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.44 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL231241 | 0.86 | HSD11B1 (0.61) | HSD11B1HSD11B2 | |
| SCHEMBL15899863 | 0.84 | HSD11B1 (0.46) | HSD11B1HSD11B2 | |
| SCHEMBL3946283 | 0.81 | HSD11B1 (0.46) | HSD11B1HSD11B2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL230984 | 0.78 | HSD11B1 (0.60) | HSD11B1HSD11B2 | |
| SCHEMBL233009 | 0.77 | HSD11B1 (0.63) | HSD11B1HSD11B2 | |
| SCHEMBL231302 | 0.77 | HSD11B1 (0.59) | HSD11B1HSD11B2 | |
| SCHEMBL3954281 | 0.76 | DRD2 (0.46) | HSD11B1EPHX2 | |
| SCHEMBL15899912 | 0.76 | HSD11B1 (0.49) | HSD11B1HSD11B2 | |
| SCHEMBL15899864 | 0.75 | HSD11B1 (0.49) | HSD11B1HSD11B2 | |
| SCHEMBL234976 | 0.75 | HSD11B1 (0.57) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009026422-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | WO | disclosed |